Acquired
melanocytic nevi are commonly found in sun exposed and unexposed human skin, but the potential for their transformation into invasive
melanoma is not clear. Therefore, a mouse model of
nevus initiation and progression was developed in C3H/HeN mice using a modified chemical
carcinogenesis protocol.
Nevi develop due to DNA damage initiated by dimethylbenz(a)
anthracene (DMBA) followed by chronic promotion with 12-O-tetradecanoyl-phorbol-13-acetate (TPA). Dysplastic pigmented skin lesions appeared in 7-9 wk with 100% penetrance. Nests of melanocytic cells appeared in a subset of skin draining lymph nodes (dLN) by 25 wk, but not in age matched controls. Immunohistochemistry, real-time PCR, and flow cytometric analyses confirmed their melanocytic origin. Transformed cells were present in a subset of
nevi and dLNs, which exhibited anchorage-independent growth,
tumor development, and
metastasis in nude mice. Approximately 50% of the cell lines contained H-Ras mutations and lost
tumor suppressor
p16(Ink4a) expression. While most studies of
melanoma focus on
tumor progression in transgenic mouse models where the mutations are present from birth, our model permits investigation of acquired mutations at the earliest stages of
nevus initiation and promotion of
nevus cell transformation. This robust
nevus/
melanoma model may prove useful for identifying genetic loci associated with
nevus formation, novel oncogenic pathways,
tumor targets for immune-prevention, screening
therapeutics, and elucidating mechanisms of immune surveillance and immune evasion.